- Technology and Data
- Front End Sales and Marketing
- Allergy
- HIV
- Women's Health
- Migraine
- Compounding
- Continuous Glucose Monitoring
- Mental Health Awareness
- Veterinary Pharmacy
- CBD
- Infectious Disease
- Eye Health
- Digestive Health
- Biosimilars
- Influenza
- Shingles
- COPD Management
- Pediatrics
- Generics
- Pain Management
- COVID-19
- Immunization
- Oncology
- Anticoagulants
- Autoimmune Diseases
- Dermatology
- Diabetes
- Respiratory
- Heart Health
- Cardiovascular Clinical Consult
FDA issues statement on ephedrine supplements
On Aug. 17, the U.S. Court of Appeals for the Tenth Circuit in Denver upheld the FDA final rule declaring all dietary supplements containing ephedrine alkaloids adulterated and, therefore, illegal for marketing in the U.S., reversing a decision by the District Court of Utah. Commenting on the Denver court's ruling, the FDA said, "The Tenth Circuit Court of Appeals' ruling demonstrates the soundness of FDA's decision to ban dietary supplements containing ephedrine alkaloids, consistent with the Dietary Supplement Health and Education Act (DSHEA) of 1994.
FDA issues statement on ephedrine supplements
On Aug. 17, the U.S. Court of Appeals for the Tenth Circuit in Denver upheld the FDA final rule declaring all dietary supplements containing ephedrine alkaloids adulterated and, therefore, illegal for marketing in the U.S., reversing a decision by the District Court of Utah. Commenting on the Denver court's ruling, the FDA said, "The Tenth Circuit Court of Appeals' ruling demonstrates the soundness of FDA's decision to ban dietary supplements containing ephedrine alkaloids, consistent with the Dietary Supplement Health and Education Act (DSHEA) of 1994. The Tenth Circuit Court of Appeals also found that Congress clearly required FDA to conduct a risk-benefit analysis under DSHEA.
To see more Hot off the Press news articles, click here http://www.drugtopics.com/Hot+off+the+Press.
Pharmacists Play Unique Role in Advancing Health Equity for Patients With Chronic Disease
December 7th 2023A new study, outlined in a poster at ASHP Midyear 2023, identified 3 key themes associated with the ways in which pharmacists are positioned to advance health equity for patients with chronic diseases.
